Zentalis Pharmaceuticals, Inc.
0.85xPrice / book
Market cap
$285.97M
Tangible equity
—
Price / tangible book
—
Price / book
0.85x
Return on equity
-49.2%
Return on assets
-38.5%
Efficiency ratio
—
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: ZNTL stock price at discount vs PNC $3.99 current versus $7.61 implied using P/B multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at PNC's multiple
Implied fair value · at ZNTL's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Filter, sort, and scan the equity metrics that matter most for banks: book value, tangible book, returns, and operating efficiency.
Multiple discount
Lower is better
Profitability lag
Asset efficiency lag
Lower is better
Statements
Bank-focused income statement and equity metrics aligned to the reporting windows.
SEC periods: ZNTL FY 2024 (ended Dec 31, 2024) · PNC FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Tangible book and profitability anchor a bank, not enterprise value.
Deposits and cash-like balances distort enterprise value for banks, so this section reads equity value, tangible book and profitability instead.
Price / book
Market cap
$285.97M
Tangible equity
—
Price / tangible book
—
Price / book
0.85x
Return on equity
-49.2%
Return on assets
-38.5%
Efficiency ratio
—
Price / tangible book
Market cap
$97.98B
Tangible equity
$49.63B
Price / tangible book
1.97x
Price / book
1.62x
Return on equity
11.5%
Return on assets
1.2%
Efficiency ratio
40.7%
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Zentalis Pharmaceuticals, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
PNC Financial Services Group, Inc. · implied price per share
Bank model off — standard DCF modelling is disabled for financial institutions.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.24x
0.94x
Net debt / EBITDA
Leverage against operating earnings
-0.29x
—
Cash and equivalents
Liquid reserves on the balance sheet
$33.90M
—
Total debt
Interest-bearing obligations outstanding
$82.57M
$57.10B
Comparable set
Where the pair sits against the wider banking comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Arcus Biosciences, Inc.
ZNTL vs RCUS
Repare Therapeutics Inc.
ZNTL vs RPTX
IDEAYA Biosciences, Inc.
ZNTL vs IDYA
Mersana Therapeutics, Inc.
ZNTL vs MRSN
EXELIXIS, INC.
ZNTL vs EXEL
JPMorgan Chase & Co.
ZNTL vs JPM
Bank of America Corporation
ZNTL vs BAC
Citigroup Inc.
ZNTL vs C
Wells Fargo & Company
ZNTL vs WFC
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.